IMMUNOCORE HLDGS ADS/1 (F:6YG) — Market Cap & Net Worth
Market Cap & Net Worth: IMMUNOCORE HLDGS ADS/1 (6YG)
IMMUNOCORE HLDGS ADS/1 (F:6YG) has a market capitalization of $1.36 Billion (€1.16 Billion) as of August 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #7527 globally and #1041 in its home market, demonstrating a -7.46% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying IMMUNOCORE HLDGS ADS/1's stock price €24.80 by its total outstanding shares 50695078 (50.70 Million). See how much does IMMUNOCORE HLDGS ADS/1 reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
IMMUNOCORE HLDGS ADS/1 Market Cap History: 2021 to 2026
IMMUNOCORE HLDGS ADS/1's market capitalization history from 2021 to 2026. Data shows change from $1.77 Billion to $1.65 Billion (-9.83% CAGR).
IMMUNOCORE HLDGS ADS/1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how IMMUNOCORE HLDGS ADS/1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.42x
IMMUNOCORE HLDGS ADS/1's market cap is 4.42 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $3.14 Billion | $174.36 Million | -$52.54 Million | 18.02x | N/A |
| 2023 | $3.62 Billion | $249.43 Million | -$55.29 Million | 14.49x | N/A |
| 2024 | $1.62 Billion | $310.20 Million | -$51.09 Million | 5.24x | N/A |
| 2025 | $1.77 Billion | $400.02 Million | -$35.51 Million | 4.42x | N/A |
Competitor Companies of 6YG by Market Capitalization
Companies near IMMUNOCORE HLDGS ADS/1 in the global market cap rankings as of August 4, 2026.
Key companies related to IMMUNOCORE HLDGS ADS/1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
IMMUNOCORE HLDGS ADS/1 Historical Marketcap From 2021 to 2026
Between 2021 and today, IMMUNOCORE HLDGS ADS/1's market cap moved from $1.77 Billion to $ 1.65 Billion, with a yearly change of -9.83%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.65 Billion | -6.71% |
| 2025 | €1.77 Billion | +8.76% |
| 2024 | €1.62 Billion | -55.08% |
| 2023 | €3.62 Billion | +15.09% |
| 2022 | €3.14 Billion | +77.85% |
| 2021 | €1.77 Billion | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of IMMUNOCORE HLDGS ADS/1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.36 Billion USD |
| MoneyControl | $1.36 Billion USD |
| MarketWatch | $1.36 Billion USD |
| marketcap.company | $1.36 Billion USD |
| Reuters | $1.36 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About IMMUNOCORE HLDGS ADS/1
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebe… Read more